Life with FSGS has become a real pain in the kidneys.

If your primary focal segmental glomerulosclerosis (FSGS) is always on your mind, it may be time to talk to your doctor about a clinical research study.

We are looking for adults 18 years of age and older who have been diagnosed with FSGS to take part in a clinical research study. The purpose of the study is to determine whether H.P. Acthar® Gel (repository corticotropin injection) is helpful for adult patients with FSGS who still have an abnormal amount of protein in their urine, despite prior treatment.

Individuals will be evaluated to determine their eligibility to participate in the study. Each patient who qualifies will receive the study drug, study-related procedures, and laboratory tests at no cost. Reimbursement for reasonable time and travel costs may also be available. Learn more about the PODOCYTE Study.